Summarize the article with AI
Retatrutide vs MariTide: The Short Answer
In their Phase 2 trials, retatrutide 12 mg reduced weight by 24.2% at 48 weeks and MariTide by up to about 20% at 52 weeks, both counted as if everyone had stayed on treatment. Retatrutide has since reported Phase 3 results, up to 28.3% at 80 weeks; MariTide's Phase 3 trials are still running. Neither is approved.
Retatrutide and MariTide, or maridebart cafraglutide, from Amgen, both activate the GLP-1 receptor, but they treat the GIP receptor in opposite ways: retatrutide activates it, along with the glucagon receptor, while MariTide blocks it. Retatrutide is a weekly injection; MariTide was given monthly or every eight weeks in its Phase 2 trial.
Their Phase 2 results can be set side by side, but not as a head-to-head comparison.
Two Opposite Approaches to GIP
GIP is a gut hormone that, like GLP-1, is released after eating. Tirzepatide and retatrutide activate its receptor. Amgen describes MariTide as a "bispecific glucagon-like peptide 1 (GLP-1) receptor agonist and glucose-dependent insulinotropic polypeptide receptor (GIPR) antagonist," made as an antibody-peptide conjugate.
That both approaches produce weight loss is one of the open questions in obesity research. The trials described here were not designed to explain it, and neither drug has been compared with the other.
Phase 2 Results Compared
MariTide's Phase 2 trial, published in the New England Journal of Medicine in June 2025, enrolled 592 adults: 465 with obesity or overweight and without type 2 diabetes, and 127 with type 2 diabetes. In those without diabetes, Amgen reported weight loss of up to about 20% at 52 weeks if taken as intended, compared with 2.6% on placebo, and 12.3% to 16.2% counting everyone randomized, compared with 2.5%. Amgen said weight loss had not plateaued by 52 weeks.
Retatrutide's 48-week Phase 2 trial, published in the same journal in 2023, reported 24.2% with 12 mg if taken as intended, compared with 2.1% on placebo. The trials differed in length, doses, dosing frequency and participants, so these figures do not show which drug works better.
Where Each Drug Stands
Retatrutide. Its developer has reported Phase 3 results from TRIUMPH-1 to TRIUMPH-4 and TRANSCEND-T2D-1. In TRIUMPH-1, published in September 2026, retatrutide 12 mg reduced weight by 25.0% at 80 weeks counting everyone randomized, compared with 3.9% on placebo. Lilly plans to submit retatrutide to the US Food and Drug Administration in the first quarter of 2027; it is not approved yet.
MariTide. In its second-quarter 2026 report, Amgen said its Phase 3 weight-management trials MARITIME-1 (without type 2 diabetes) and MARITIME-2 (with type 2 diabetes) were ongoing. It is also enrolling Phase 3 trials in cardiovascular disease, heart failure and obstructive sleep apnea, a trial of people switching from weekly tirzepatide or semaglutide to MariTide every eight weeks or every quarter, and extension studies of weight-loss maintenance, with dosing as infrequent as quarterly in one of them. Amgen has not reported Phase 3 results.
Side Effects
For both drugs, gastrointestinal side effects were the most common. Amgen said MariTide's were predominantly limited to the first doses and were reduced by starting at a lower dose and increasing it, with up to 7.8% stopping because of gastrointestinal side effects in the groups that used dose escalation. In retatrutide's trials they were mostly mild or moderate and most common while the dose was being increased, and the trials also reported dysesthesia, an abnormal skin sensation (see retatrutide side effects). The trials are too different for a reliable comparison.
What Is Still Unknown
- How MariTide performs in Phase 3, and how it compares with other next-generation drugs such as CagriSema.
- How the two compare in the same trial; we found no head-to-head study announced by either company.
- Whether either drug will be approved, and the long-term safety of both.
Sources
- Jastreboff AM, et al. Once-Monthly Maridebart Cafraglutide for the Treatment of Obesity — A Phase 2 Trial. N Engl J Med. Published June 23, 2025. DOI: 10.1056/NEJMoa2504214.
- Amgen. Company announcement on MariTide Phase 2 results. June 2025.
- Amgen. Second quarter 2026 financial results and pipeline update. 2026.
- Jastreboff AM, Kaplan LM, Frías JP, et al. Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023;389(6):514–526.
- Jastreboff AM, Kaplan LM, Davies MJ, et al. Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity. N Engl J Med. Published September 29, 2026. DOI: 10.1056/NEJMoa2604169. (TRIUMPH-1)
- Eli Lilly. Lilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials, delivering significant improvements in weight and A1C. July 23, 2026.
Medical Disclaimer: This article compares published trial results for general information only and is not medical advice. Retatrutide and MariTide (maridebart cafraglutide) are investigational and neither is approved by the FDA for any use. Neither is available by prescription, and products sold online under the retatrutide name are not sold or supplied by Lilly. Nothing here is a recommendation to use, seek out or avoid any medication.
Frequently asked questions
MariTide, or maridebart cafraglutide, is an investigational weight-loss drug from Amgen that activates the GLP-1 receptor and blocks the GIP receptor. In its Phase 2 trial, given monthly or every eight weeks, it reduced weight by up to about 20% at 52 weeks if taken as intended. It is in Phase 3 and not approved.
That cannot be said. They have not been tested against each other. In separate Phase 2 trials, retatrutide 12 mg reduced weight by 24.2% at 48 weeks and MariTide by up to about 20% at 52 weeks, both if taken as intended, but the trials differed in design.
This is not fully understood. Retatrutide and tirzepatide activate the GIP receptor, while MariTide blocks it, and all of them produce weight loss together with GLP-1 activation. The trials of these drugs were not designed to explain why. Several explanations have been proposed, but none has been confirmed.
In its second-quarter 2026 report, Amgen said its Phase 3 weight-management trials MARITIME-1 and MARITIME-2 were ongoing and that further Phase 3 trials in heart disease, heart failure and sleep apnea were enrolling. Amgen has not reported Phase 3 results.



